Sinovac Initiates Phase II Volunteer Enrollment For Split Viron Pandemic Influenza (H5N1) Vaccine
Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, announced the initiation of volunteer enrollment in its Phase II clinical trial for its split pandemic influenza vaccine. The preliminary results from this study are expected to be available in early 2009.
